Maladie de kimura: À propos d’un cas

Introduction :  Mots-clés : Maladie de Kimura, parotide, chirurgie.La maladie de Kimura ou lymphogranulome éosinophile est une pathologie inflammatoire chronique très rare, d’étiologie inconnue. Nous rapportons un cas de maladie de Kimura à localisation parotidienne et à travers une revue de la littérature, rappelons les principales caractéristiques cliniques, paracliniques, thérapeutiques et évolutives de cette pathologie. Matériel et méthodes : Patient de 17 ans qui a consulté devant l’apparition d’une tuméfaction de la région parotidienne gauche évoluant depuis un an et sans paralysie faciale. Résultats : L’échographie cervico-parotidienne a révélé une parotide gauche hypertrophiée siège de multiples nodules hypoéchogènes. La tomodensitométrie cervico-faciale a mis en évidence une glande parotide gauche augmentée de taille et de structure hétérogène nodulaire sans adénopathies cervicales. La cytopontion était non concluante. Le patient a bénéficié d’une parotidectomie exofaciale gauche et l’étude anatomopathologique de la pièce opératoire revenue en faveur de la maladie de Kimura. Les suites opératoires étaient simples. Le recul est d’un an sans récidive. Discussion : La Maladie de Kimura se caractérise cliniquement par des nodules sous cutanés de localisation cervicofaciale, une augmentation du volume des glandes salivaires et des adénopathies satellites. Son diagnostic est histologique reposant sur l’identification d’une hyperplasie follicullaire avec des abcès à polynucléaires éosinophiles. Le traitement est chirurgical le plus souvent mais dans certains cas la corticothérapie est proposée. Ce diagnostic doit cependant rester à l’esprit devant toute masse cervico-faciale

Metabolic syndrome does not affect sustained virologic response of direct-acting antivirals while hepatitis C clearance improves hemoglobin A1c.

AimTo determine whether successful treatment with directacting antivirals (DAA) is associated with improvements in hemoglobin A1c (HbA1c) and if type 2 diabetes mellitus (T2DM) or metabolic syndrome affects sustained virologic response (SVR).MethodsWe performed a retrospective analysis of all hepatitis C virus (HCV) patients at the VA Greater Los Angeles Healthcare System treated with varying DAA therapy between 2014-2016. Separate multivariable logistic regression was performed to determine predictors of HbA1c decrease ≥ 0.5 after DAA treatment and predictors of SVR 12-wk post treatment (SVR12).ResultsA total of 1068 patients were treated with DAA therapy between 2014-2016. The presence of T2DM or metabolic syndrome did not adversely affect SVR12. 106 patients had both HCV and T2DM. Within that cohort, patients who achieved SVR12 had lower mean HbA1c pre treatment (7.35 vs 8.60, P = 0.02), and lower mean HbA1c post-treatment compared to non-responders (6.55 vs 8.61, P = 0.01). The mean reduction in HbA1c after treatment was greater for those who achieved SVR12 than for non-responders (0.79 vs 0.01, P = 0.03). In adjusted models, patients that achieved SVR12 were more likely to have a HbA1c decrease of ≥ 0.5 than those that did not achieve SVR12 (adjusted OR = 7.24, 95%CI: 1.22-42.94).ConclusionIn HCV patients with T2DM, successful treatment with DAA was associated with a significant reduction in HbA1c suggesting that DAA may have a role in improving insulin sensitivity. Furthermore, the presence of T2DM or metabolic syndrome does not adversely affect SVR12 rates in patients treated with DAA

Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort.

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. HCV cure has been linked to improved patient outcomes. In the era of direct-acting antivirals (DAAs), HCV cure has become the goal, as defined by sustained virological response 12 weeks (SVR12) after completion of therapy. Historically, African-Americans have had lower SVR12 rates compared to White people in the interferon era, which had been attributed to the high prevalence of non-CC interleukin 28B (IL28B) type. Less is known about the association between race/ethnicity and SVR12 in DAA-treated era. The aim of the study is to evaluate the predictors of SVR12 in a diverse, single-center Veterans Affairs population. We conducted a retrospective study of patients undergoing HCV therapy with DAAs from 2014 to 2016 at the VA Greater Los Angeles Healthcare System. We performed a multivariable logistic regression analysis to determine predictors of SVR12, adjusting for age, HCV genotype, DAA regimen and duration, human immunodeficiency virus (HIV) status, fibrosis, nonalcoholic fatty liver disease (NAFLD) fibrosis score, homelessness, mental health, and adherence. Our cohort included 1068 patients, out of which 401 (37.5%) were White people and 400 (37.5%) were African-American. Genotype 1 was the most common genotype (83.9%, N = 896). In the adjusted models, race/ethnicity and the presence of fibrosis were statistically significant predictors of non-SVR. African-Americans had 57% lower odds for reaching SVR12 (adj.OR = 0.43, 95% CI = 1.5-4.1) compared to White people. Advanced fibrosis (adj.OR = 0.40, 95% CI = 0.26-0.68) was also a significant predictor of non-SVR. In a single-center VA population on DAAs, African-Americans were less likely than White people to reach SVR12 when adjusting for covariates

Anabasis articulata (Forssk.) Moq. food aqueous extract triggers oxidative stress-induced senescence and reduces metastatic power in MDA-MB-231 cells

Ancient ethnobotanical practices handed down through traditional knowledge are still commonly employed to treat various pathologies, although the scientific reasons underlying their biological effects have not been clarified yet. In this contribution, the potential antitumoral activity of the aqueous extract from A. articulata (AAE) was investigated to validate the hypothesis of the Algerian folk medicine which would suggest this plant derivative as a functional food for treating breast cancer. A. articulata phytocomplex, isolated by maceration following exactly the African recipe, has been already characterized by our research group in previous works. Thus, the antiproliferative function of AAE against MDA-MB-231, a highly aggressive human breast adenocarcinoma cell line, was evaluated. Slowing down of cell growth, absence of cytotoxicity and DNA fragmentation, and cell cycle arrest at the G2/M phase were observed after treatment with AAE at different doses (0.3–6 mg of dried plant material equivalent per mL of culture medium) for 24 and 48 h. Wound and transwell assays proved that AAE possessed both antimigration and antiinvasive capacities, evidence also supported by molecular analyses focused on Metalloproteases (MMP-2 and MMP-9), Vimentin and ανβ3-Integrin. These results, together with the demonstration of the activation of p53/p21WAF1/Cip1/p27Kip1 pathway and the increase of oxygen reactive species levels, suggested that AAE triggered a senescence process. The final confirmation was obtained by a specific kit staining senescent cells. All our data would explain the efficacy of the Algerian medicinal remedy based on the intake of the investigated functional plant food and would highlight the basics for developing novel natural pharmacological products based on AAE and showing preventive and therapeutic antineoplastic potentialities against highly aggressive breast cancers

Nutraceutical Content and Biological Properties of Lipophilic and Hydrophilic Fractions of the Phytocomplex from Pistacia atlantica Desf. Buds, Roots, and Fruits

The aim of the present investigation was to obtain 12 aqueous extracts and 1 oil from Pistacia atlantica Desf. subsp. atlantica specimens. The samples differed for processed plant organs (i.e., roots, buds, and fruits), gender and geographical station of the collected trees. Total phenols, flavonoids, and condensed tannins were determined, revealing that bud extracts exhibited the highest phenolic content (386.785 ± 16.227 mg GAE/g DM), followed by fruit and root preparations. Similar results were detected for flavonoids and tannins, whose quantitation ranged from 0.014 ± 0.005 to 74.780 ± 9.724 mg CE/g DM and from 0.037 ± 0.003 to 14.793 ± 0.821 mg CE/g DM, respectively. The biochemical profile of the extracts was further characterized by HPLC-DAD, in terms of specific phenolics. This analysis identified gallic acid as a typical metabolite for ripe fruit, while hydroxytyrosol for female roots and male buds. In parallel, P. atlantica fruit oil was profiled by GC-MS analysis, which detected 37 lipophilic components, including palmitic acid (the major component, ~55%), anacardol, tetradecanol, arachidic acid, squalene, and some terpenes. The samples revealed interesting antioxidant activity, with EC50 values ranging from 0.073 ± 0.001 to 193.594 ± 28.942 mg/mL and from 0.029 ± 0.001 to 103.086 ± 20.540 mg/mL, in that order, for DPPH and reducing power assays. Concerning the total antioxidant capacity, the results ranged from 0.053 ± 0.008 to 51.648 ± 1.659 mg AAE/g DM. Finally, the antimicrobial potential of the plant extracts was estimated against 7 bacterial species and 2 fungal strains, known to be human pathogens, demonstrating a good antibiotic effect for the bud extracts. All these findings strongly suggest that P. atlantica would represent a natural reservoir for novel additives to be used in therapeutic, food, and cosmetic products

The Certification of ATLAS Thin Gap Chambers Produced in Israel and China

Thin gap chambers (TGCs) are used for the muon trigger system in the forward region of the LHC experiment ATLAS. A TGC consists of a plane of closely spaced wires maintained at positive high voltage, sandwiched between resistive grounded cathode planes with an anode wire to cathode plane gap distance smaller than the wire-to-wire spacing. The TGCs are expected to provide a trigger signal within 25 ns of the bunch spacing of the LHC accelerator, with an efficiency exceeding 95%, while exposed to an effective photon and neutron background ranging from 30 to 500 Hz/cm2. About 2,500 out of the 3,600 ATLAS TGCs are being produced at the Weizmann institute in Israel, and in Shandong University in China. Once installed in the ATLAS detector the TGCs will be inaccessible. A vigorous production quality control program is therefore implemented at the production sites. Furthermore, after chamber completion, a thorough program of quality assurance is implemented to ensure the efficient performance of the chambers during more than ten years of operation in the LHC high rate environment. This program consists of a detailed mapping of the detectors response using cosmic rays, as well as checking the chambers behavior using a high rate radiation source. An aging test performed on five chambers in a serial gas connection is presented. Finally the results of the chambers certification tests performed at CERN before the installation in ATLAS are described.Comment: Presented at 2004 IEEE Nuclear Science Symposium 2004, Rome, Oct 200

The Cosmic Ray Hodoscopes for Testing Thin Gap Chambers at the Technion and Tel Aviv University

Thin gap chambers (TGCs) are built for the muon trigger chambers in the endcap region of the LHC experiment ATLAS. More than 2500 ATLAS TGCs are being produced at the Weizmann institute in Israel, and in Shandong University in China. Detailed testing of these chambers is performed at the Technion and at the Tel-Aviv University. Two cosmic ray hodoscopes for testing the operation of these detectors were built in Israel. In these hodoscopes the response of the chambers to energetic cosmic ray muons is recorded and analyzed. The hodoscopes measure the exact time and space location of the cosmic ray hit and read out the chambers which are being tested to verify that they produce a corresponding signal within the required time interval. The cosmic ray hodoscopes built at the Technion and at the Tel Aviv University for the test of ATLAS TGCs are described. The mechanical structure, readout electronics, data acquisition and operating scheme are presented. Typical TGC test results are presented and discussed

Enhancing droplet-based single-nucleus RNA-seq resolution using the semi-supervised machine learning classifier DIEM

Single-nucleus RNA sequencing (snRNA-seq) measures gene expression in individual nuclei instead of cells, allowing for unbiased cell type characterization in solid tissues. We observe that snRNA-seq is commonly subject to contamination by high amounts of ambient RNA, which can lead to biased downstream analyses, such as identification of spurious cell types if overlooked. We present a novel approach to quantify contamination and filter droplets in snRNA-seq experiments, called Debris Identification using Expectation Maximization (DIEM). Our likelihood-based approach models the gene expression distribution of debris and cell types, which are estimated using EM. We evaluated DIEM using three snRNA-seq data sets: (1) human differentiating preadipocytes in vitro, (2) fresh mouse brain tissue, and (3) human frozen adipose tissue (AT) from six individuals. All three data sets showed evidence of extranuclear RNA contamination, and we observed that existing methods fail to account for contaminated droplets and led to spurious cell types. When compared to filtering using these state of the art methods, DIEM better removed droplets containing high levels of extranuclear RNA and led to higher quality clusters. Although DIEM was designed for snRNA-seq, our clustering strategy also successfully filtered single-cell RNA-seq data. To conclude, our novel method DIEM removes debris-contaminated droplets from single-cell-based data fast and effectively, leading to cleaner downstream analysis. Our code is freely available for use at https://github.com/marcalva/diem.Peer reviewe